Studying the charts after a massive stock market drop is always fun. It brings excitement but more importantly opportunity. I always look at the three biggest time frames when looking for a major top or bottom in a stock or a market. In this case I am focussing on the S&P 500. I analyzed the three main chart time frames, the daily, weekly and monthly. The next step is to find a level that is significant on all three time frames. In other words, a pivot, moving average, trend line..ect, where the price is the same on each time frame.

I found it and it excites me because it shows exactly where to place my buy order for a bounce in the stock market. Find a great trade level is always exciting because it brings with it the likelihood of making thouands of Dollars in profit.

Read more: These 3 Time Frames Confirm S&P 500 Buy Target For Massive Drop

Home Depot quickened its sell-off on Friday as the stock market tumbled. There is a major support level coming into view at $124.70. This level is a double bottom from June 2016 and should create a solid bounce in the stock. This is a swing trade which means you are not married to Home Depot, instead hold it for a few days to weeks looking for a bounce to approximately $130.00, then sell.

Read more: Home Depot Buy Level May Hit Tomorrow If Stock Market Flushes Again

A real stock market goes up and down based on real things. Like earnings, economic news and other normal factors. When a stock market can drop in one day on the whiff of an interest rate hike, erasing over 40 days of neutral to upside in a single thrust, you know something is definitely wrong. That is what happened this past Friday. The stock market has been in a 1.75% range for over 40 days, and one person simply suggests the Federal Reserve might raise interest rates and the whole world comes crashing down. This isn't a stock market, it is a sham created by the Federal Reserve through manipulation. 

When someone or somebody manipulates something so drastically that it no longer trades on fundamentals, it can crash on the simple suggestion the Federal Reserve is taking away the drugs. The Federal Reserve is responsible for every bubble in history, the most recent was the financial collapse. Let's not forget that after the tech bubble burst in the late 1990's and the economy struggled in the early 2000's, the Federal Reserve lowered interest rates making home buyers see how cheap it was to buy a home. Thus the bubble formed and eventually burst. It is just a simple repeat here. Thank you Federal Reserve. Your wise actions have made the world much, much better (sarcasm). The bottom line is, as a stock investor and trader, we trade anything. This just gives smart investors more opportunities to profit. However, you have to feel bad for average investors who get their nuts handed to them, losing their hard earned money.

By -Anthony Jackson

It took just THREE days for 48 days of gains and sideways action to be wiped out for the Colgate-Palmolive Company (NYSE: CL). Most investors would stay clear of $CL after this big drop, but the smart investor is looking for major support to buy and profit from a short-term bounce. I have found that support on the $CL charts. It is at $70 which is very near Friday's close of $70.86. You can see on the daily chart, the 200 moving average is at $69.91. There is also a gap fill at $69.99 that hasn’t yet been filled, and a 0.25 fib retrace at $69.25. These are just half of the factors I see in this general area, so it should be very good support for a bounce back to $73 at least. I'll be looking for a pierce of $70 to jump in on the long side.

By Pro-Trader

Caralee Carlson

CEO Note: The Dilemma in Funding Zika and Other Pandemic Therapies

SAN DIEGO - September 9, 2016 (Investorideas.com newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

After a seven-week vacation, the U.S. Congress and Senate returned to work on Tuesday and immediately restarted the fight to advance a Zika virus funding program. Beyond normal political posturing, government officials face the dilemma of whether to allocate resources to support the advancement of traditional drugs and vaccines or emerging broad-spectrum therapies. As it relates to viral pandemics, there is often an assumptive complacency that drug and vaccine cures are just a matter of spending sufficient capital resources. In reality, the effort to align a disease-specific drug or vaccine with an emerging pandemic threat is immensely challenging and not often successful. Especially in the case of a virulent pathogen that may prohibit human studies from being conducted to demonstrate treatment efficacy.

Read more: Aethlon Medical ( AEMD )